| Ytd | -70.05% | |
| 1y | -80.78% |
| Open | 0.23 | Prev Close | 0.23 | Low | 0.23 | High | 0.24 | Mkt Cap | 12.90M |
| Vol | 1.72M | Avg Vol | 1.21M | EPS | -0.67 | P/E | -0.34 | Forward P/E | -1.18 |
| Beta | 1.93 | Short Ratio | 10.47 | Inst. Own | 12.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.81 | 200-d Avg | 0.87 | 1yr Est | 11.50 |
PDSB News
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PD
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the compan
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul
"Dear Fellow Shareholders,Over the past several months, our Board of Directors and management te
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PD
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated
PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biot
PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Durat
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“P
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Ca
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innova
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Pr
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Pro
PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) traded down 1.9% during trading on Tu
New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Ant
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo
Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated
Stocks That Hit 52-Week Lows On Monday